Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-containing chemotherapy and one programmed death-ligand 1 checkpoint inhibitor

Atezolizumab in combination with cabozantinib is in development for the treatment of metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer in the UK. It causes symptoms such as a persistent cough, coughing up blood, recurrent or long chest infections, unexplained breathlessness and wheezing, and hoarseness. Metastatic NSCLC is when the cancer starts in the lungs and then spreads to other areas of the body. Current treatment options for NSCLC patient who have progressed after treatment are limited.